| Summary: | Predominant inflammatory immunological patterns as well as the depletion of CD4<sup>+</sup> T cells during nonalcoholic fatty liver disease (NAFLD) are reported to be associated with the progression of hepatocellular carcinoma (HCC). Here, we report that an LRP-1 agonistic peptide, SP16, when administered during advanced NAFLD progression, restored the depleted CD4<sup>+</sup> T cell population but did not significantly affect the inflammatory immunological pattern. This data suggests that restoration of CD4<sup>+</sup> T cells without modulation of the hepatic immunological pattern is not sufficient to prevent HCC. However, SP16 administered early during NAFLD progression modulated the inflammatory profile. Future studies will determine if regulation of the inflammatory immune response by SP16 early in NAFLD progression will prevent HCC.
|
|---|